T Cells Targeting MAGE-A4 Shrink Tumors

    Cancer Discovery
    |June 17, 2020
    PubMed

    Insights

    Engineered T cells targeting MAGE-A4 cancer antigens show promise against solid tumors. This immunotherapy, ADP-A2M4, demonstrated significant tumor shrinkage and manageable side effects in early trials.

    Area of Science:

    • Oncology
    • Immunotherapy
    • Cancer Research

    Background:

    • Solid tumors present significant treatment challenges.
    • Cancer testis antigens like MAGE-A4 are potential therapeutic targets.
    • Autologous T cell therapy offers a personalized approach to cancer treatment.

    Related Concept Videos